JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Early Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Imvanex
Biological: Shingrix
Biological: Candin
Other: Skin Biopsy
Biological: LPS
Other: Saline Control

First Posted Date: 2019-05-16

Last Posted Date: 2020-01-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT03953196

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

Conditions: Diabetes Mellitus, Type 1

First Posted Date: 2019-05-10

Last Posted Date: 2023-04-13

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT03945903

Locations: 🇺🇸
Rady Children's Hospital, San Diego, California, United States

A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: JNJ-72537634
Biological: Placebo

First Posted Date: 2019-04-30

Last Posted Date: 2024-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 31

Registration Number: NCT03931447

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: JNJ-63898081

First Posted Date: 2019-04-24

Last Posted Date: 2022-11-07

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT03926013

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 4 locations

A Study of Itraconazole in the Management of Superficial Fungal Infections in India

Phase 4

Terminated

Conditions: Mycoses

Interventions: Drug: Itraconazole

First Posted Date: 2019-04-22

Last Posted Date: 2021-09-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT03923010

Locations: 🇮🇳
Yenepoya Medical College, Mangalore, India
🇮🇳
Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India
🇮🇳
Sri Ramachandra Medical Centre, Chennai, India

and more 1 locations

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

Interventions: Drug: JNJ-67571244

First Posted Date: 2019-04-16

Last Posted Date: 2023-07-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 68

Registration Number: NCT03915379

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 14 locations

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Lenalidomide

First Posted Date: 2019-04-03

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 200

Registration Number: NCT03901963

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Oncology Associates, PC - HAL, Glendale, Arizona, United States

and more 67 locations

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Phase 1

Active, not recruiting

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin

Interventions: Drug: JNJ-67856633

First Posted Date: 2019-04-03

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 226

Registration Number: NCT03900598

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States

and more 44 locations

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Phase 2

Completed

Conditions: Arthroplasty, Replacement, Knee

Interventions: Drug: JNJ-70033093 200 mg
Drug: JNJ-70033093 50 mg
Drug: JNJ-70033093 25 mg
Drug: JNJ-70033093 100 mg
Drug: Enoxaparin 40 mg
Drug: Placebo

First Posted Date: 2019-03-27

Last Posted Date: 2022-07-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1242

Registration Number: NCT03891524

Locations: 🇧🇪
Ziekenhuis Oost-Limburg, Genk, Belgium
🇭🇺
Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary
🇦🇷
Clínica Adventista Belgrano, Caba, Argentina

and more 114 locations

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Drospirenone/Ethinylestradiol
Drug: Midazolam
Drug: JNJ-64530440

First Posted Date: 2019-03-26

Last Posted Date: 2021-03-26

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT03890341

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy